Biohit Group’s Net Sales outlook for 2020 changed

The coronavirus (2019-nCoV) has impacted negatively on the demand of the company’s products globally and due to that Biohit Group’s Net Sales outlook for 2020 has changed.

Read more

Does an undiagnosed atrophic gastritis (acid-free stomach) increase the risk of coronavirus infection, its complications and mortality particularly among elderly people?

Read more

Coronavirus Information

Dear Partner, 

At this time of global struggle against the coronavirus, Biohit Oyj strives to ensure that our employee´s and partners remain healthy. We have already taken several actions in accordance with guidelines of the Finnish government authorities, incl. allowing office workers to work solely from home.  

At the time of writing, there have been no disruptions to kit production. Our factory remains open and we are serving our customers as best as we can. There are certain challenges related to air freight (e.g. airlines have cancelled many flights) and this can manifest in higher freight charges or longer transport duration.  

Please contact our Customer Services ( for the latest information regarding the handling of your order. 

Additional information 
CEO Semi Korpela, Biohit Oyj 
tel. +358 9 773 861 

Biohit in brief 

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. 

Biohit Oyj Financial Calendar, Financial Reporting and Annual General Meeting in 2020

Biohit Oyj Financial Calendar, Biohit Oyj’s Financial Reporting and Annual General Meeting in 2020.

Read more

TREATMENT RECOMMENDATION IN RUSSIA: GastroPanel®-biomarkers should be used for detection of gastrointestinal diseases

The Ministry of Health of the Russian Federation’s recommendation for early detection of gastrointestinal diseases is published in the Journal of Gastroenterology, Hepatology, Coloproctology.

Read more


Biohit Oyj Half Year Financial Report 14 August 2019 at 9:30 am local time (EET)

Read more

Two clinical trials with Acetium® capsule for prevention of migraine-type headache have been concluded

In 2014, Biohit Oyj initiated two clinical trials for prevention of migraine-type headache attacks, testing the efficacy of Acetium® capsule. Because of a slow patient enrollment, the trial was subsequently extended to two additional clinical centers abroad. Read more